4.7 Article

A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma

Journal

NANOSCALE HORIZONS
Volume 5, Issue 8, Pages 1213-1225

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d0nh00077a

Keywords

-

Funding

  1. Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2013R1A6A3A01064606, 2015-R1A6A3A04059360]
  2. Bio & Medical Technology Development Program of the NRF of Korea - Ministry of Science ICT [2018-M3A9H3021707]
  3. Basic Science Research Program through the NRF of Korea - Ministry of Education [2018-R1A6A1-A03025124, 2018-R1D1A1B07043383]
  4. U.S. National Institutes of Health [1R01CA214550-01]
  5. Medical Research Center Program through the NRF of Korea - Ministry of Science and ICT [2017-R1A5A2014768]
  6. National Research Foundation of Korea [2013R1A6A3A01064606] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Organ-specific cell-penetrating peptides (CPPs) are a class of molecules that can be highly effective at delivering therapeutic cargoes, and they are currently of great interest in cancer treatment strategies. Herein, we describe a new CPP (amino acid sequence serine-isoleucine-tyrosine-valine, or SIWV) that homes to glioblastoma multiforme (GBM) brain tumor tissues with remarkable specificity in vitro and in vivo. The SIWV sequence was identified from an isoform of annexin-A3 (AA3H), a membrane-interacting human protein. The mechanism of intracellular permeation is proposed to follow a caveolin-mediated endocytotic pathway, based on in vitro and in vivo receptor inhibition and genetic knockdown studies. Feasibility as a targeting agent for therapeutics is demonstrated in a GBM xenograft mouse model, where porous silicon nanoparticles (pSiNPs) containing the clinically relevant anticancer drug SN-38 are grafted with SIWV via a poly-(ethylene glycol) (PEG) linker. The formulation shows enhanced in vivo targeting ability relative to a formulation employing a scrambled control peptide, and significant (P < 0.05) therapeutic efficacy relative to free SN-38 in the GBM xenograft animal model.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available